tirzepatide surmount 1 after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial SURMOUNT-1 (NEJM 2022) tested tirzepatide
Description
As patients with lupus nephritis are at risk of CKD progression, they would all benefit from interdisciplinary care to minimize the risk of kidney failure, cardiovascular disease and infections
The National Academy of Sciences Press, Washington DC
The medication is administered once weekly via subcutaneous injection, with doses gradually titrated to minimise gastrointestinal side effects
When comparing semaglutide to other weight loss treatments, one can appreciate its unique advantages
Variants in the GLP1R gene, such as rs6923761, influence how effectively your cells respond to the medication and may affect the optimal dose for your body
